Anda belum login :: 04 Jul 2022 06:06 WIB
Detail
ArtikelOut in The Open  
Oleh: [s.n]
Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Nature Biotechnology: The Science and Business of Biotechnology vol. 23 no. 2 (Feb. 2005), page 153-154.
Topik: BIOTECHOLOGY; out in the open
Ketersediaan
  • Perpustakaan Pusat (Semanggi)
    • Nomor Panggil: NN9.2
    • Non-tandon: 1 (dapat dipinjam: 0)
    • Tandon: tidak ada
    Lihat Detail Induk
Isi artikelUntil recently, biotech and pharmaceutical companies have had little reason to heed calls for greater transparency in the disclosure data from their clinical trials. That all changed last year when new york state attorney general eliot splitzed field a high profile lawsuit against Glaxo Smith Kline (GSK) alleging that the company had with held trial data indicating that its antidepressant seroxat (paroxetine) increased the risk of suicide in children. For some reason, the data revealing increased suicide in children. For some reason, the data revealing increased suicide risk were mysteriously absent from official GSK summaries of seroxat's clinical performance. As part of its settlement with new york state in september, GSK admitted no wrong doing but agreed to post data on its website...
Opini AndaKlik untuk menuliskan opini Anda tentang koleksi ini!

Kembali
design
 
Process time: 0.03125 second(s)